Enhance Your Research with TD2’s Metabolomics & Proteomics Services
Elevate your cancer drug discovery research with TD2’s cutting-edge Metabolomics and Proteomics Services for in vivo oncology studies. Metabolomic and proteomic analysis can be used in the preclinical and early clinical stages of drug development to assess the efficacy, safety, and drug-target mapping of potential cancer drugs. This information can help you make informed decisions about which drug candidates to pursue further, reducing attrition rates and streamlining your drug development process. Our commitment to delivering meaningful data allows you to focus on your research and make groundbreaking discoveries.
Experience the Benefits of TD2’s Metabolomic and Proteomic Services:
- Broad Coverage: Our untargeted assays deliver comprehensive coverage of small molecules and metabolites.
- Versatile applications: Biomarker development, new target identification, off-target effects, population-based studies, and patient stratification
- Combined Proteomics: Enrich your metabolomics data by incorporating specialized proteomics assays.
- Simplified Data Analysis: We take care of the complex data processing, presenting you with a clear and concise data analysis report.
In-Depth Global Metabolomics Profiling for Maximum Insights
Our suite of complementary LC/MS assays offers a wide-ranging view of the small molecule landscape, ensuring you have the most complete data at your fingertips. Our platform is designed to analyze various chemicals, including lipids and central carbon metabolites, using a selection of assays.